Publications by authors named "Sadao Jinno"
Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study.
Rheumatology (Oxford)
September 2024
Objectives: To investigate the predictive factors for difficult-to-treat rheumatoid arthritis (D2T RA) and assess the efficacy of biologic DMARDs (bDMARDs) and Janus kinase inhibitors (JAKi).
Methods: Retrospective analysis was conducted on data from the ANSWER cohort comprising 3623 RA patients treated with bDMARDs or JAKi in Japan. Multivariate Cox proportional hazards modelling was used to analyse the hazard ratios (HRs) for treatment retention.
Article Synopsis
- The study aimed to explore how large joint involvement (LJI) impacts disease activity and medication retention in rheumatoid arthritis (RA) patients starting biological therapies or Janus kinase inhibitors.
- Researchers analyzed data from 1721 patients, finding that LJI led to significant improvements in disease activity at 24 weeks, but patients with LJI had higher overall disease activity levels.
- Although drug retention rates were similar between patients with and without LJI, the findings suggest that early treatment strategies, particularly using interleukin-6 receptor inhibitors, could benefit those with LJI.
Comparison of retention of biologics in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study.
Rheumatology (Oxford)
February 2025
Article Synopsis
- A multicentre, retrospective study analyzed the retention rates and reasons for stopping treatment in elderly patients with rheumatoid arthritis (EORA), comparing Janus kinase inhibitors (JAKi) to biologic disease-modifying drugs.
- The study found that IL-6 inhibitors had better retention rates than TNF inhibitors, while JAKi showed lower discontinuation due to ineffectiveness but higher rates of discontinuation due to adverse events compared to TNF inhibitors.
- The conclusions suggest that while IL-6i and JAKi are effective for EORA patients, the increased risk associated with JAKi requires careful consideration and a tailored treatment approach.
Aim: Validity of Algorithms in Large Databases: Infectious Diseases, Rheumatoid Arthritis, and Tumor Evaluation in Japan (VALIDATE-J) study examined algorithms for identifying rheumatoid arthritis (RA) in Japanese claims data.
Methods: VALIDATE-J was a multicenter, cross-sectional retrospective study. Disease-identifying algorithms were used to detect RA diagnosed between January 2012 and December 2016 using claims data from two Japanese hospitals.
Article Synopsis
- This study evaluated the effectiveness and safety of four JAK inhibitors (tofacitinib, baricitinib, peficitinib, and upadacitinib) in treating rheumatoid arthritis in a real-world setting, focusing on reducing bias and adjusting for patient characteristics.
- A total of 622 patients were analyzed, with no significant differences found in retention rates, disease activity scores, or remission rates among the various treatment groups after 6 months.
- Key predictive factors for treatment efficacy included baseline disease activity and previous treatment history, but overall, the four drugs showed similar effectiveness and safety in managing rheumatoid arthritis.
Article Synopsis
- The study aimed to assess changes in disease activity among elderly RA patients over 75 years old in Japan from 2014 to 2021.
- Data showed an increase in the percentage of elderly patients achieving remission and low disease activity (LDA), with rates rising from 62.2% to 78.2% during that time.
- Factors that positively influenced remission and LDA included the use of methotrexate, while glucocorticoid use and previous b/tsDMARDs treatments negatively impacted these outcomes.
Background: To validate Japanese claims-based disease-identifying algorithms for herpes zoster (HZ), Mycobacterium tuberculosis (MTB), nontuberculous mycobacteria infections (NTM), and Pneumocystis jirovecii pneumonia (PJP).
Methods: VALIDATE-J, a multicenter, cross-sectional, retrospective study, reviewed the administrative claims data and medical records from two Japanese hospitals. Claims-based algorithms were developed by experts to identify HZ, MTB, NTM, and PJP cases among patients treated 2012-2016.
Objectives: Anaemia, a common comorbidity of RA, is related to high disease activity and poor prognosis. It is unknown which biologic/targeted synthetic (b/ts)-DMARDs are optimal for patients with anaemia and RA in regulating anaemia and controlling disease activity.
Methods: We investigated the change in haemoglobin (Hb) levels, drug retention rates and disease activities after the administration of b/ts-DMARDs with different modes of action [TNF inhibitors (TNFis), immunoglobulin fused with cytotoxic T-lymphocyte antigen (CTLA-4-Ig), IL-6 receptor inhibitors (IL-6Ris) and Janus kinase inhibitors (JAKis)] in patients with RA stratified by baseline Hb levels using the multicentre observational registry for patients with RA in Japan (ANSWER cohort).
Objectives: This multicenter, retrospective study evaluated the effectiveness of add-on methotrexate (MTX) or iguratimod (IGU) in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors (JAKis).
Methods: Forty-five patients were treated with new additional MTX (n = 22) or IGU (n = 23) and followed for 6 months. Patients' background is as follows: age, 59.
Article Synopsis
- This study analyzed factors affecting the retention of Janus kinase inhibitors (JAKi) like baricitinib (BAR) and tofacitinib (TOF) in rheumatoid arthritis (RA) patients across multiple centers.
- It found that the main reasons for discontinuation were ineffectiveness (22.3%), toxic adverse events (13.3%), non-toxic reasons (7.2%), with no discontinuations due to remission.
- Key risk factors for discontinuation included a history of anti-IL-6R ineffectiveness, age (≥ 75 years), high doses of prednisone (≥ 5 mg/day), and being female; while prior treatments and the type of JAKi did not significantly impact discontinu
We compared the prophylactic effect of trimethoprim-sulfamethoxazole (TMP-SMX) with atovaquone for pneumocystis pneumonia (PCP) in patients with connective tissue diseases (CTDs) receiving high-dose glucocorticoids. Patients with CTDs aged ≥ 18 years who were treated with a prolonged course (≥ 4 weeks) of glucocorticoids (≥ 20 mg/day prednisone) in a Japanese tertiary center between 2013 and 2017 were included. The patients were categorized into two groups: TMP-SMX and atovaquone group.
View Article and Find Full Text PDFValidity of claims-based algorithms for selected cancers in Japan: Results from the VALIDATE-J study.
Pharmacoepidemiol Drug Saf
September 2021
Purpose: Real-world data from large administrative claims databases in Japan have recently become available, but limited evidence exists to support their validity. VALIDATE-J validated claims-based algorithms for selected cancers in Japan.
Methods: VALIDATE-J was a multicenter, cross-sectional, retrospective study.
Objective: We aimed to investigate the efficacy of anti-IL-6 receptor antibody (aIL-6) and other biologic disease-modifying antirheumatic drugs (bDMARDs), such as TNF inhibitor and CTLA4-Ig in the treatment of rheumatoid arthritis (RA) in patients with knee joint involvement.
Methods: We retrospectively analyzed 1059 treatment courses of patients with RA who visited our hospitals and were treated with bDMARDs. We categorized them into two groups, with or without knee joint involvement.
Background: This multi-center, retrospective study aimed to clarify retention rates and reasons for discontinuation of either tumor necrosis factor inhibitors (TNFi) or interleukin-6 inhibitors (IL-6i) in patients with elderly-onset rheumatoid arthritis (EORA).
Methods: Patients with rheumatoid arthritis (RA) enrolled in a Japanese multicenter observational registry between 2011 and 2020 were included. EORA was defined as RA with onset at 60 or over.
Objectives: The aim of this multicenter, retrospective study was to clarify the retention rates of sarilumab (SAR), baricitinib (BAR), and tofacitinib (TOF) in patients with rheumatoid arthritis (RA).
Methods: Patients treated with either SAR (n = 62), BAR (n = 166), or TOF (n = 185) (females, 80.9%; age, 61.
The objective of the study was to compare the efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) between elderly-onset rheumatoid arthritis (EORA) and young-onset rheumatoid arthritis (YORA) patients. Patients with rheumatoid arthritis (RA) aged ≧18 years enrolled in a Japanese multicenter observational registry between 2009 and 2018 who had moderate or high disease activity when initiating bDMARDs were included. EORA was defined as RA with onset at 60 or over.
View Article and Find Full Text PDFObjectives: The aim of this multicenter, retrospective study was to clarify the retention of secondary biological disease-modifying antirheumatic drugs (bDMARDs) or Janus kinase inhibitors (JAKi) in patients with rheumatoid arthritis (RA) who were primarily treated by tocilizumab (TCZ) or abatacept (ABT) as first bDMARDs.
Method: Patients who were treated by either TCZ (n = 145) or ABT (n = 76) and then switched to either tumor necrosis factor inhibitors (TNFi), TCZ, ABT, or JAKi (including only cases switched from TCZ) from 2001 to 2019 (female 81.0%, age 59.
A family history of rheumatoid arthritis (RA) is a strong risk factor for developing RA, affecting both genetically and environmentally. However, whether family history provides clinically relevant information in the modern classification and treatment remains largely unknown. This study aimed to determine whether a family history of RA is associated with a different clinical presentation of RA and treatment response.
View Article and Find Full Text PDFBackground: The aim of this study is to evaluate the retention rates and reasons for discontinuation for seven biological disease-modifying antirheumatic drugs (bDMARDs) in a real-world setting of elderly patients (65 years of age or older) with rheumatoid arthritis (RA).
Methods: This multi-center, retrospective study assessed 1,098 treatment courses of 661 patients with bDMARDs from 2009 to 2018 (females, 80.7%; baseline age, 71.
Following publication of the original article [1], the authors noticed that two corrections were not implemented during the production process.
View Article and Find Full Text PDFBackground: The aim of this study is to evaluate the retention rates and reasons for discontinuation for seven biological disease-modifying antirheumatic drugs (bDMARDs) in a real-world setting of patients with rheumatoid arthritis (RA).
Methods: This multi-center, retrospective study assessed 4466 treatment courses of 2494 patients with bDMARDs from 2009 to 2017 (females, 82.4%; baseline age, 57.
Trends in Hospitalizations for Serious Infections in Patients With Rheumatoid Arthritis in the US Between 1993 and 2013.
Arthritis Care Res (Hoboken)
April 2018
Objective: The epidemiology of hospitalizations with infections among patients with rheumatoid arthritis (RA) is unknown, despite an increase in RA treatments that confer a risk of infection.
Methods: We examined National Inpatient Sample data from 1993-2013. We identified hospitalizations among adults with RA, defined by International Classification of Diseases, Ninth Revision, Clinical Modification codes (714.